World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
35923
World Ranking
14873
National Ranking
209

Overview

Juan José Lahuerta is affiliated with the Complutense University of Madrid in Spain. Their research primarily focuses on Medicine and Biochemistry, Genetics and Molecular Biology. The work spans several subfields including Hematology, Molecular Biology, Oncology, Genetics, and Immunology.

The scientist's main research topics include Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis, Amyloidosis: Diagnosis, Treatment, Outcomes, Cancer Treatment and Pharmacology, Myeloproliferative Neoplasms: Diagnosis and Treatment, and Chronic Lymphocytic Leukemia Research.

Juan José Lahuerta has contributed substantially to scholarly literature. Selected recent papers include:

  • Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project, 2022, Journal of Clinical Oncology
  • Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial, 2021, The Lancet Oncology
  • Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma, 2020, Blood
  • Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma, 2020, Blood
  • Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma, 2020, Blood Cancer Journal

The frequent collaborators of Juan José Lahuerta include Jesús F. San Miguel, María-Victoria Mateos, Joaquin Martínez-López, Albert Oriol, and Noemí Puig.

Regarding publication venues, contributions have appeared most often in:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • Blood Cancer Journal
  • Blood Advances

Best Publications

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • International staging system for multiple myeloma.

    Philip R. Greipp;Jesus San Miguel;Brian G.M. Durie;John J. Crowley

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

  • Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    J Flores-Montero;L Sanoja-Flores;B Paiva;N Puig

  • Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

    María-Victoria Mateos;Miguel-Teodoro Hernández;Pilar Giraldo;Javier de la Rubia

  • Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

    María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez

  • Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

    Laura Rosiñol;Albert Oriol;Ana Isabel Teruel;Dolores Hernández

  • Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

    María-Victoria Mateos;María-Victoria Mateos;José-M. Hernández;José-M. Hernández;Miguel-T. Hernández;Miguel-T. Hernández;Norma-C. Gutiérrez;Norma-C. Gutiérrez

  • Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

    Bruno Paiva;Maria-Belén Vidriales;Jorge Cerveró;Gema Mateo

  • Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

    Joaquin Martinez-Lopez;Juan J. Lahuerta;François Pepin;Marcos González

  • Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    C. Fernández De Larrea;R. A. Kyle;B. G.M. Durie;H. Ludwig

  • Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

    Meletios A. Dimopoulos;Jens Hillengass;Saad Usmani;Elena Zamagni

  • Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

    Juan José Lahuerta;Maria Victoria Mateos;Joaquin Martínez-López;Laura Rosiñol

  • High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

    Bruno Paiva;Norma C. Gutiérrez;Laura Rosiñol;María-Belén Vídriales

  • International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    Jens Hillengass;Saad Usmani;S Vincent Rajkumar;Brian G M Durie

  • A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.

    Laura Rosiñol;José Antonio Pérez-Simón;Anna Sureda;Javier de la Rubia

  • Autologous Stem-Cell Transplantation for Hodgkin’s Disease: Results and Prognostic Factors in 494 Patients From the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group

    A Sureda;R Arranz;A Iriondo;E Carreras

  • Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

    María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez

  • Erratum: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (Leukemia (2012) 26 (149-157) DOI: 10.1038/leu.2011.196)

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

Frequent Co-Authors

Maria-Victoria Mateos
Maria-Victoria Mateos University of Salamanca
Joan Bladé
Joan Bladé University of Barcelona
Albert Oriol
Albert Oriol Autonomous University of Barcelona
Jesús F. San Miguel
Jesús F. San Miguel University of Navarra
Ramón García-Sanz
Ramón García-Sanz University of Salamanca
Anna Sureda
Anna Sureda Autonomous University of Barcelona
Alberto Orfao
Alberto Orfao University of Salamanca
Felipe Prosper
Felipe Prosper University of Navarra
Michele Cavo
Michele Cavo University of Bologna
María José Calasanz
María José Calasanz University of Navarra

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical careers in the USA extends beyond traditional MD programs. Many students consider alternative or complementary online degrees that offer flexible learning and diverse pathways into healthcare.

For those interested in healthcare leadership, enrolling in one of the cheapest mha online programs can be a cost-effective route to management roles in hospitals and clinics. Nurses aiming to advance their practice can explore cheapest bsn to dnp programs, designed for working RNs who wish to achieve a terminal degree in nursing.

If pharmacy is your focus, consider accredited online pharm d programs to gain the qualifications needed for advanced roles in pharmaceuticals, research, and patient care. Additionally, those looking for entry-level positions in the rapidly growing field of health data may start with a reputable him associate degree online.

These flexible, affordable online options provide valuable alternatives to traditional medical degrees and open up varied career opportunities in healthcare.

Best Scientists Citing Juan José Lahuerta

Trending Scientists

Recently Published Articles